BioSpace News Archive

Biora Therapeutics, Inc. announced that the United States Patent and Trademark Office has issued a patent related to the company’s technologies for oral, systemic delivery of biologics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.

Nacuity Pharmaceuticals, Inc. and Arctic Therapeutics International, today announced the companies have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of NPI-001 in Iceland for the treatment of hereditary cystatin C amyloid angiopathy (HCCAA).

Eton Pharmaceuticals today announced the acquisition of betaine anhydrous for oral solution.

EDGC, a company specializing in genomic analysis and precision medicine, announced on the 13th that Sam Martin has been hired as the Vice President of Overseas Business Development.

The global Infectious Disease Therapeutics market size was estimated at USD 115 billion in 2021 and is expected to surpass around USD 167 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 4.23% during the forecast period 2022 to 2030.

TC Biopharm (Holdings) PLC (“TC Biopharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW) today announced that it has received approval from the UK regulatory body MHRA to apply an 18-month extrapolated shelf life to its current allogeneic cell therapy product, OmnImmune®.

Brain research and advocacy non-profit Cohen Veterans Bioscience (CVB) announces the publication of results from its digital health research program analyzing data from the Parkinson’s Progression Markers Initiative (PPMI) to detect the presence or absence of Parkinson’s disease (PD).

Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) has appointed Melissa Tosca as Executive Vice President of Finance.

Microtech, a wholly owned subsidiary of Medinol, Inc., a leader in global MedTech research and development, announced that its implantable microsensor platform will be presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation on Friday, September 16.

FEMSelect, the developer of EnPlace®, a minimally invasive, meshless approach to pelvic floor ligament fixation, reported positive results in a four-year prospective follow-up evaluation of the system.